文献速递临床试验与 GCP

两剂埃博拉疫苗方案(Ad26.ZEBOV 后接 MVA-BN-Filo)在健康成年孕妇中的安全性、反应原性与免疫原性:一项 3 期开放标签随机对照试验的研究方案

Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial.
PubMed 文献 · Trials · 2022-06-20

该研究方案为在卢旺达西部产前保健机构招募 2000 名成年(≥18 岁)孕妇的随机、开放标签、单中心 3 期临床试验,按 1:1 随机接受两剂埃博拉疫苗方案(A 组)或不接种(B 组)。主要目标是评估至产后 1.5 个月内的母婴不良结局及至出生后 3.5 个月内的新生儿/婴儿不良结局,并报告反应原性、免疫原性及抗体持久性。研究旨在支持放宽孕妇使用限制的标签变更。

要点

  • 2000 名成年孕妇按 1:1 随机分为接种两剂埃博拉疫苗组(A 组)和不接种对照组(B 组)。
  • 主要目标为评估至产后 1.5 个月的母婴不良结局及至出生后 3.5 个月的新生儿/婴儿不良结局。
  • 将在 150 名孕妇与 150 名产后接种的非孕妇中比较免疫原性,并评估 75 名婴儿的母体抗体持久性。

核心结论

  • 研究旨在支持放宽孕妇使用限制的标签变更,该人群为医疗需求高的脆弱人群。

研究设计与样本

  • 随机、开放标签、单中心 3 期临床试验,从卢旺达西部产前保健机构招募 2000 名成年(≥18 岁)孕妇。
  • 按 1:1 随机接受两剂埃博拉疫苗方案(Ad26.ZEBOV、MVA-BN-Filo,A 组)或不接种(B 组)。

主要发现

  • 主要目标为评估随机分组孕妇至产后 1.5 个月内的母婴不良结局及至出生后 3.5 个月内的新生儿/婴儿不良结局。
  • 将报告从随机分组或出生至研究结束期间女性和新生儿所有严重不良事件的发生频率及相关性。
  • 将在 150 名预期孕期完成两剂接种的孕妇(A 组 1000 名接种孕妇的子集)与 150 名产后接种的非孕妇(B 组子集)中比较免疫原性。
  • 将评估 A 组子集 75 名婴儿的母体抗体持久性。
  • 探索性分析包括 A 组对两剂疫苗方案的可接受性,以及 50 名 A 组女性和 10 名对照(B 组接种前女性)母乳中的母体抗体。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Risks to mother and fetus following Ebola virus infection are very high. Evaluation of safety and immunogenicity of non-replicating Ebola vaccine candidates is a priority for use in pregnant women. This is the protocol for a randomized, open-label, single-center phase 3 clinical trial of the safety, reactogenicity, and immunogenicity of the 2-dose Ebola vaccine regimen in healthy adult pregnant women. This 2-dose regimen has been shown to be safe, judged effective, and approved in non-pregnant populations. METHODS: A total of 2000 adult (≥ 18 years of age) pregnant women will be enrolled from antenatal care facilities in Western Rwanda and randomized (1:1) to receive the 2-dose Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo (group A)) or control (unvaccinated pregnant women (group B)). The primary objectives are to (1) assess adverse maternal/fetal outcomes in randomized pregnant women up to 1.5 months after delivery and (2) assess adverse neonatal/infant outcomes in neonates/infants born to randomized women up to 3.5 months after birth. The frequency and relatedness of all serious adverse events in women and newborns from randomization or birth, respectively, until study end will be reported. The reactogenicity and unsolicited adverse events of the 2-dose Ebola vaccine regimen in all vaccinated pregnant women (group A) will be reported. We will also assess the immunogenicity of the 2-dose Ebola vaccine regimen in 150 pregnant women who are anticipated to receive both vaccine doses within the course of their pregnancy (a subset of the 1000 pregnant vaccinated women from group A) compared to 150 non-pregnant women vaccinated after delivery (a subset of group B). The persistence of maternal antibodies in 75 infants born to women from the group A subset will be assessed. Exploratory analyses include assessment of acceptability of the 2-dose Ebola vaccine regimen among group A and assessment of maternal antibodies in breast milk in 50 women from group A and 10 controls (women from group B prior to vaccination). DISCUSSION: This study is intended to support a label variation to relax restrictions on use in pregnant women, a vulnerable population with high medical need. TRIAL REGISTRATION: Clinicaltrials.gov NCT04556526 . September 21, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Karita E, Nyombayire J, Ingabire R, et al. Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial. Trials. 2022. PMID: 35725488. doi:10.1186/s13063-022-06360-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。